 |
|
|
|
 |
|
|
| Article 1 to 5 out of 5 concerning Elbion AG
|
-
elbion Merges With 4AZA to Form European Drug Discovery and Development Company
(12/08/2006)
elbion AG announced it has merged with 4AZA Bioscience NV, Belgium, to form a European company for discovery and development of drugs for CNS and immunological diseases. The combined company, to be called elbion NV ("elbion"), will be headquartered ...
-
elbion AG appoints Dr. Thomas Taapken as Chief Financial Officer and Member of the Executive Board
(09/23/2005)
elbion AG announced that Dr. Thomas Taapken has been appointed Chief Financial Officer by the supervisory board of the company.Taapken (40), previously spent 3 years as a Partner in the life science team of DVC, Deutsche Venture Capital, and was a ...
-
elbion AG Increases Series A Financing to EUR35 Million
(05/30/2005)
elbion AG (elbion) announced that it has increased its Series A Financing from EUR25 million to EUR35 million. Additional investors include Techno Venture Management (TVM), Munich and Boston, Temasek Holdings, Singapore, and Mitsubishi Corporation, ...
-
Glaxosmithkline and Elbion to Collaborate on Development and Commercialisation of a new DE IV Inhibitor
(01/25/2005)
GlaxoSmithKline plc (GSK) and elbion AG announce that they have signed a worldwide agreement to collaborate on the development and commercialisation of elbion's phosphodiesterase (PDE) IV inhibitor, AWD 12-281 and associated back-up compounds. AWD ...
-
elbion AG Completes EUR 25 Million Series A Financing
(01/11/2005)
Elbion AG (elbion), announced that it has secured a EUR 25 million first round of venture capital financing. The private placement was co-led by 3i (Munich, Germany), Burrill & Company (San Francisco, USA) and DVC Deutsche Venture Capital (Munich, ...
Additional information
Elbion AG
Radebeul, Germany
Company
|
|
|
|
|
|
Top
